Heron Therapeutics

About:

Heron Therapeutics is a biotechnology firm specializing in polymer-based pharmaceuticals.

Website: http://herontx.com

Top Investors: Hercules Capital, Deep Track Capital, Great Point Partners, Rubric Capital Management, Tang Capital Management

Description:

Heron Therapeutics is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The company’s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.